Pharvaris isn't a household name, but its lead drug — deucrictibant — is quietly building a compelling case in hereditary angioedema (HAE). With fresh clinical data just presented at EAACI 2026 and analysts pegging fair value at $47 against a current price of $31.46, the setup here is worth a look.
The trade: sell the $30 put expiring July 17 for $0.97, collecting roughly 3.2% premium in 30 days on a strike that sits 4.6% below the current price. Annualized, that's north of 38%. For a biotech, that's not shocking — but the risk-reward framing matters. The $30 strike is actually below the 50-day MA of $29.68, which means you're selling into a stock that's been trending above that level and is now sitting comfortably above it. The 200-day MA at $26.28 provides a deeper technical floor if things get ugly.
The negative beta of -2.33 is the quirky detail that demands attention. PHVS tends to move opposite the broader market, which in a volatile macro environment can actually be a feature rather than a bug. If equities sell off, PHVS doesn't necessarily follow. That said, biotech is biotech — binary data readouts, FDA timelines, and enrollment updates can gap a stock in either direction faster than any delta hedge can save you. The IV at 46.6% reflects that reality, and it's also why the premium is as generous as it is.
The EAACI conference presentations are a near-term catalyst worth tracking. Pharvaris presented data supporting a differentiated profile for deucrictibant — positioning it against existing HAE therapies like lanadelumab and berotralstat. If the HAE community reception is positive, it reinforces the bull case that analysts are already pricing into that $47 target. The annual general meeting announcement is routine noise, but it signals the company is operating normally — no emergency liquidity events, no surprise restructurings.
Watch for any follow-up commentary from EAACI attendees or analyst updates post-conference. If the $31.46 price level holds through the next two weeks of conference digestion, this put likely expires worthless. The risk scenario is a broader biotech selloff or unexpected clinical commentary that drags shares back toward the low $20s — in which case, assignment at $30 means owning PHVS at an effective cost basis of $29.03 with analysts still at $47.
Today's Atlas Trades
STEP — Short Put
- Strike: $45.0
- Expiration: 2026-07-17
- Premium: $1.33
- Stock Price: $48.31
- IV: 51.0%
- Delta: -0.281
- DTE: 30
HRI — Short Put
- Strike: $140.0
- Expiration: 2026-07-17
- Premium: $4.1
- Stock Price: $150.87
- IV: 51.8%
- Delta: -0.275
- DTE: 30
KEP — Short Put
- Strike: $12.5
- Expiration: 2026-07-17
- Premium: $0.37
- Stock Price: $13.23
- IV: 46.6%
- Delta: -0.304
- DTE: 30
BOOT — Short Put
- Strike: $150.0
- Expiration: 2026-07-17
- Premium: $4.52
- Stock Price: $162.52
- IV: 54.2%
- Delta: -0.270
- DTE: 30
CNH — Short Put
- Strike: $10.0
- Expiration: 2026-07-17
- Premium: $0.3
- Stock Price: $10.51
- IV: 45.3%
- Delta: -0.319
- DTE: 30
GEN — Short Put
- Strike: $23.0
- Expiration: 2026-07-17
- Premium: $0.74
- Stock Price: $24.57
- IV: 52.2%
- Delta: -0.296
- DTE: 30
CXT — Short Put
- Strike: $40.0
- Expiration: 2026-07-17
- Premium: $1.29
- Stock Price: $42.88
- IV: 53.1%
- Delta: -0.290
- DTE: 30
APPF — Short Put
- Strike: $150.0
- Expiration: 2026-07-17
- Premium: $5.09
- Stock Price: $157.89
- IV: 49.1%
- Delta: -0.324
- DTE: 30
EFXT — Short Put
- Strike: $22.5
- Expiration: 2026-07-17
- Premium: $0.66
- Stock Price: $23.68
- IV: 44.9%
- Delta: -0.314
- DTE: 30
TCMD — Short Put
- Strike: $25.0
- Expiration: 2026-07-17
- Premium: $0.72
- Stock Price: $26.43
- IV: 45.5%
- Delta: -0.303
- DTE: 30
PHVS — Short Put
- Strike: $30.0
- Expiration: 2026-07-17
- Premium: $0.97
- Stock Price: $31.46
- IV: 46.6%
- Delta: -0.328
- DTE: 30
NNI — Short Put
- Strike: $125.0
- Expiration: 2026-07-17
- Premium: $3.98
- Stock Price: $130.95
- IV: 45.7%
- Delta: -0.329
- DTE: 30